查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1388042

全球癌症生物標記市場：份額、規模、趨勢、產業分析 - 按類型、生物分子、應用、細分市場預測，2023-2032 年

Cancer Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Breast, Prostate, Colorectal, Cervical, Liver, Lung Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, And Segment Forecasts, 2023-2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

預計到 2032 年，全球癌症生物標記市場規模將達到 533.6 億美元。 該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

針對新型癌症生物標記的藥物開發不斷加大努力和投資，在推動癌症生物標記市場的成長潛力方面發揮關鍵作用。 這些生物標記作為癌細胞特定特徵的指標，有助於開發更有針對性和更有效的治療方法。 透過關注這些獨特的生物標記物，製藥公司可以開發針對特定癌症亞型的藥物，從而改善治療結果並減少副作用。

此外，技術先進的伴隨診斷試劑盒的推出將補充標靶治療的開發。 這些診斷試劑盒有助於識別患者體內是否存在特定的生物標記物，使醫療保健專業人員能夠根據患者的個人資料製定個人化的治療計劃。 這些診斷試劑盒指導下的個人化醫療可確保患者獲得最佳治療，從而產生更好的治療反應並改善患者的整體治療結果。

政府支持的旨在推動新型癌症診斷技術的措施也推動了成長。 例如，美國國家癌症研究所 (NCI) 向超過八個專門致力於開發癌症生物標記的研究領域分配資金。 英國癌症研究中心、肺癌研究基金會和美國國立衛生研究院等其他組織也透過資助以生物標記為中心的研究計畫發揮重要作用。 這些措施正在促進該領域的創新和研究，並加速新癌症診斷技術的進步。

大量飲酒、吸煙、飲食不健康以及久坐生活方式的人比生活方式健康的人更容易患癌症。研究發現，患癌症的可能性高出 80% 此外，某些感染，如人類乳突病毒 (HPV)、EB 病毒、B型肝炎病毒和幽門螺旋桿菌，也正在研究它們與癌症發展的可能關聯。

癌症生物標記市場報告亮點

由於乳癌病例數量不斷增加、生物標記的廣泛研究以及主要產品的推出，乳癌獲得了最大的市場份額

由於患有遺傳疾病和相關疾病情況的患者數量不斷增加，遺傳生物標記正在迅速增長

由於個人化治療方案的最新進展，個人化醫療可能會快速成長。

由於消費者意識、熟練外科醫生的存在以及更好的醫療基礎設施，北美在 2022 年佔據了最大的市場份額。

主要參與者包括Abbott Laboratories、Thermo Fisher Scientific、Affymetrix、Illumina、Agilent Technologies、Merck、Hologic、Roche、QIAGEN、Sino Biological、Becton等。

目錄

第 1 章簡介

第 2 章執行摘要

第 3 章研究方法

第 4 章全球癌症生物標記市場洞察

  • 癌症生物標記市場 - 生物分子概況
  • 癌症生物標記市場動態
    • 促進因素和機會
    • 抑制因素和挑戰
  • PESTEL 分析
  • 癌症生物標記市場的生物分子趨勢
  • 價值鏈分析
  • 新冠肺炎 (COVID-19) 影響分析

第 5 章全球癌症生物標記市場（按類型）

  • 主要發現
  • 簡介
  • 乳癌
  • 攝護腺癌
  • 大腸癌
  • 子宮頸癌
  • 肝癌
  • 肺癌
  • 其他

第 6 章全球癌症生物標記市場（按應用）

  • 主要發現
  • 簡介
  • 藥物發現/開發
  • 診斷
  • 個人化醫療
  • 其他

第 7 章全球癌症生物標記市場（按生物分子）

  • 主要發現
  • 簡介
  • 遺傳生物標記
  • 表觀遺傳生物標記
  • 代謝生物標記
  • 蛋白質體學生物標誌物
  • 其他

第 8 章全球癌症生物標記市場（按地區）

  • 主要發現
  • 簡介
    • 2019-2032 年癌症生物標記市場評估（按地區）
  • 癌症生物標記市場 - 北美
    • 北美：癌症生物標記市場（按類型），2019-2032 年
    • 北美：癌症生物標記市場，依生物分子劃分，2019-2032 年
    • 北美：癌症生物標記市場，按應用劃分，2019-2032 年
    • 癌症生物標記市場 - 美國
    • 癌症生物標記市場 - 加拿大
  • 癌症生物標記市場 - 歐洲
    • 歐洲：癌症生物標記市場（按類型），2019-2032 年
    • 歐洲：癌症生物標記市場，依生物分子分類，2019-2032 年
    • 歐洲：癌症生物標記市場，按應用劃分，2019-2032 年
    • 癌症生物標記市場 - 英國
    • 癌症生物標記市場 - 法國
    • 癌症生物標記市場 - 德國
    • 癌症生物標記市場 - 義大利
    • 癌症生物標記市場 - 西班牙
    • 癌症生物標記市場 - 荷蘭
    • 癌症生物標記市場 - 俄羅斯
  • 癌症生物標記市場 - 亞太地區
    • 亞太地區：癌症生物標記市場（按類型），2019-2032 年
    • 亞太地區：癌症生物標記市場，依生物分子劃分，2019-2032 年
    • 亞太地區：癌症生物標記市場，按應用劃分，2019-2032 年
    • 癌症生物標記市場—中國
    • 癌症生物標記市場—印度
    • 癌症生物標記市場 - 馬來西亞
    • 癌症生物標記市場 - 日本
    • 癌症生物標記市場 - 印尼
    • 癌症生物標記市場－韓國
  • 癌症生物標記市場 - 中東和非洲
    • 中東和非洲：癌症生物標記市場（按類型），2019-2032 年
    • 中東和非洲：癌症生物標記市場，按生物分子分類，2019-2032 年
    • 中東和非洲：癌症生物標記市場，按應用劃分，2019-2032 年
    • 癌症生物標記市場 - 沙烏地阿拉伯
    • 癌症生物標記市場－阿拉伯聯合大公國
    • 癌症生物標記市場 - 以色列
    • 癌症生物標記市場 - 南非
  • 癌症生物標記市場 - 拉丁美洲
    • 拉丁美洲：癌症生物標記市場（按類型），2019-2032 年
    • 拉丁美洲：癌症生物標記市場，按生物分子分類，2019-2032 年
    • 拉丁美洲：癌症生物標記市場，按應用劃分，2019-2032 年
    • 癌症生物標記市場—墨西哥
    • 癌症生物標記市場 - 巴西
    • 癌症生物標記市場－阿根廷

第 9 章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協議/揭露

第 10 章公司簡介

  • Abbott Laboratories
  • Agilent Technologies
  • Affymetrix
  • Becton
  • Hologic
  • Illumina
  • Merck
  • QIAGEN
  • Roche
  • Sino Biological
  • Thermo Fisher Scientific
Product Code: PM3738

The global cancer biomarkers market size is expected to reach USD 53.36 billion by 2032, according to a new study by Polaris market research. The report "Cancer Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Breast, Prostate, Colorectal, Cervical, Liver, Lung Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, And Segment Forecasts, 2023-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing initiatives and investments in the development of drugs that target novel cancer biomarkers play a crucial role in driving the growth potential of the cancer biomarkers market. These biomarkers serve as indicators of specific characteristics of cancer cells, enabling the development of more targeted and effective treatments. By focusing on these unique biomarkers, pharmaceutical companies can create drugs tailored to specific subtypes of cancer, leading to improved treatment outcomes and reduced side effects.

Moreover, the introduction of technologically advanced companion diagnostic kits complements the development of targeted therapies. These diagnostic kits help identify the presence of specific biomarkers in patients, allowing healthcare professionals to personalize treatment plans based on individual patient profiles. Personalized medicine, guided by these diagnostic kits, ensures that patients receive the most suitable treatments, leading to better treatment responses and enhanced overall patient outcomes.

Growth is also facilitated by the existence of supportive government initiatives aimed at advancing novel cancer diagnostic techniques. For instance, the National Cancer Institute (NCI) allocates funding to over 8 research areas specifically focused on the development of cancer biomarkers. Other organizations such as Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health also play a significant role by providing funding for research projects centered around biomarkers. These initiatives foster innovation and research in the field, accelerating the progress of new and improved cancer diagnostic techniques.

Individuals who engage in high alcohol consumption, use tobacco, have unhealthy dietary habits, and lead a sedentary lifestyle are found to be 80% more susceptible to developing cancer compared to those with healthier habits. Additionally, certain infections, including Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori, have also been under study for their potential association with cancer development.

Cancer Biomarkers Market Report Highlights

Breast cancer held the largest share, owing to the rising cases of breast cancer, extensive research on biomarkers, & key product launches

Genetic biomarkers will grow at the rapid pace, because of rising cases of genetic disorders, and relevant diseased scenario

Personalized medicine will grow at rapid pace, owing recent advancements in personalized treatment options

North America held the largest share of the market in 2022, owing to consumer awareness, presence of skilled surgeons with better healthcare infrastructure

Key players include Abbott Laboratories, Thermo Fisher Scientific, Affymetrix, Illumina, Agilent Technologies, Merck, Hologic, Roche, QIAGEN, Sino Biological, & Becton

Polaris market research has segmented the cancer biomarkers market report based on type, biomolecule, application, and region:

Cancer Biomarkers, Type Outlook (Revenue - USD Billion, 2023 - 2032)

  • Breast cancer
  • Prostate cancer
  • Colorectal cancer
  • Cervical cancer
  • Liver cancer
  • Lung cancer
  • Others

Cancer Biomarkers, Biomolecule Outlook (Revenue - USD Billion, 2023 - 2032)

  • Genetic Biomarkers
  • Epigenetic Biomarkers
  • Metabolic Biomarkers
  • Proteomic Biomarkers
  • Others

Cancer Biomarkers, Application Outlook (Revenue - USD Billion, 2023 - 2032)

  • Drug discovery and Development
  • Diagnostics
  • Personalized medicine
  • Others

Cancer Biomarkers, Regional Outlook (Revenue - USD Billion, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Cancer Biomarkers Market Insights

  • 4.1. Cancer Biomarkers Market - Biomolecule Snapshot
  • 4.2. Cancer Biomarkers Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing awareness among patients and healthcare professionals about the importance of early diagnosis of malignancies.
      • 4.2.1.2. Rising demand for personalized medicine
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High capital investment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Cancer Biomarkers Market Biomolecule Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Cancer Biomarkers Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Breast cancer
    • 5.3.1. Global Cancer Biomarkers Market, by Breast cancer, by Region, 2019-2032 (USD Billion)
  • 5.4. Prostate cancer
    • 5.4.1. Global Cancer Biomarkers Market, by Prostate cancer, by Region, 2019-2032 (USD Billion)
  • 5.5. Colorectal cancer
    • 5.5.1. Global Cancer Biomarkers Market, by Colorectal cancer, by Region, 2019-2032 (USD Billion)
  • 5.6. Cervical cancer
    • 5.6.1. Global Cancer Biomarkers Market, by Cervical cancer, by Region, 2019-2032 (USD Billion)
  • 5.7. Liver cancer
    • 5.7.1. Global Cancer Biomarkers Market, by Liver cancer, by Region, 2019-2032 (USD Billion)
  • 5.8. Lung cancer
    • 5.8.1. Global Cancer Biomarkers Market, by Lung cancer, by Region, 2019-2032 (USD Billion)
  • 5.9. Others
    • 5.9.1. Global Cancer Biomarkers Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Cancer Biomarkers Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Drug discovery and Development
    • 6.3.1. Global Cancer Biomarkers Market, by Drug discovery and Development, by Region, 2019-2032 (USD Billion)
  • 6.4. Diagnostics
    • 6.4.1. Global Cancer Biomarkers Market, by Diagnostics, by Region, 2019-2032 (USD Billion)
  • 6.5. Personalized medicine
    • 6.5.1. Global Cancer Biomarkers Market, by Personalized medicine, by Region, 2019-2032 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Cancer Biomarkers Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Cancer Biomarkers Market, by Biomolecule

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • 7.3. Genetic Biomarkers
    • 7.3.1. Global Cancer Biomarkers Market, by Genetic Biomarkers, By Region, 2019-2032 (USD Billion)
  • 7.4. Epigenetic Biomarkers
    • 7.4.1. Global Cancer Biomarkers Market, by Epigenetic Biomarkers, By Region, 2019-2032 (USD Billion)
  • 7.5. Metabolic Biomarkers
    • 7.5.1. Global Cancer Biomarkers Market, by Metabolic Biomarkers, By Region, 2019-2032 (USD Billion)
  • 7.6. Proteomic Biomarkers
    • 7.6.1. Global Cancer Biomarkers Market, by Proteomic Biomarkers, By Region, 2019-2032 (USD Billion)
  • 7.7. Others
    • 7.7.1. Global Cancer Biomarkers Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Cancer Biomarkers Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Cancer Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Cancer Biomarkers Market - North America
    • 8.3.1. North America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.3.3. North America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.3.4. Cancer Biomarkers Market - U.S.
      • 8.3.4.1. U.S.: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.3.5. Cancer Biomarkers Market - Canada
      • 8.3.5.1. Canada: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 8.4. Cancer Biomarkers Market - Europe
    • 8.4.1. Europe: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.4. Cancer Biomarkers Market - UK
      • 8.4.4.1. UK: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.5. Cancer Biomarkers Market - France
      • 8.4.5.1. France: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.6. Cancer Biomarkers Market - Germany
      • 8.4.6.1. Germany: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.7. Cancer Biomarkers Market - Italy
      • 8.4.7.1. Italy: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.8. Cancer Biomarkers Market - Spain
      • 8.4.8.1. Spain: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.9. Cancer Biomarkers Market - Netherlands
      • 8.4.9.1. Netherlands: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.10. Cancer Biomarkers Market - Russia
      • 8.4.10.1. Russia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 8.5. Cancer Biomarkers Market - Asia Pacific
    • 8.5.1. Asia Pacific: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.4. Cancer Biomarkers Market - China
      • 8.5.4.1. China: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.5. Cancer Biomarkers Market - India
      • 8.5.5.1. India: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.6. Cancer Biomarkers Market - Malaysia
      • 8.5.6.1. Malaysia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.7. Cancer Biomarkers Market - Japan
      • 8.5.7.1. Japan: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.8. Cancer Biomarkers Market - Indonesia
      • 8.5.8.1. Indonesia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.9. Cancer Biomarkers Market - South Korea
      • 8.5.9.1. South Korea: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 8.6. Cancer Biomarkers Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.4. Cancer Biomarkers Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.5. Cancer Biomarkers Market - UAE
      • 8.6.5.1. UAE: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.6. Cancer Biomarkers Market - Israel
      • 8.6.6.1. Israel: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.7. Cancer Biomarkers Market - South Africa
      • 8.6.7.1. South Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 8.7. Cancer Biomarkers Market - Latin America
    • 8.7.1. Latin America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.7.4. Cancer Biomarkers Market - Mexico
      • 8.7.4.1. Mexico: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.7.5. Cancer Biomarkers Market - Brazil
      • 8.7.5.1. Brazil: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.7.6. Cancer Biomarkers Market - Argentina
      • 8.7.6.1. Argentina: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Agilent Technologies
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Affymetrix
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Becton
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Hologic
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Illumina
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Merck
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. QIAGEN
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Roche
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Sino Biological
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Thermo Fisher Scientific
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development

List of Tables

  • Table 1 Global Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Global Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 4 Cancer Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 7 North America: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 8 U.S.: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 10 U.S.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 11 Canada: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 13 Canada: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 14 Europe: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Europe: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 17 UK: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 19 UK: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 20 France: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 22 France: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 23 Germany: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 25 Germany: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 26 Italy: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 28 Italy: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 29 Spain: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 31 Spain: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 35 Russia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 37 Russia: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 41 China: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 43 China: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 44 India: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 46 India: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 50 Japan: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Japan: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 56 South Korea: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 58 South Korea: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 65 UAE: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 67 UAE: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 68 Israel: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 70 Israel: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 71 South Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 73 South Africa: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 74 Latin America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 76 Latin America: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 77 Mexico: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 79 Mexico: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 80 Brazil: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 82 Brazil: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 83 Argentina: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 85 Argentina: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Cancer Biomarkers Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Application
  • Figure 7. Global Cancer Biomarkers Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Cancer Biomarkers Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Biomolecule
  • Figure 11. Global Cancer Biomarkers Market, by Biomolecule, 2022 & 2032 (USD Billion)
  • Figure 12. Cancer Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Cancer Biomarkers Market